Gynecologic oncology is a specialized area of medicine dedicated to the treatment of cancers affecting the female reproductive system. This includes using surgical and/or chemotherapy for cervical, endometrial, ovarian, uterine, vulvar cancers and gestational trophoblastic disease. Operating out of the Juravinski Cancer Centre, the division of gynecologic oncology services the geographic area including Hamilton and the Wellington, Waterloo, Niagara, Haldimand and Brant Counties.
The team services Thunder Bay’s Local Health Integration Network (LHIN) with monthly outpatient clinics at the Thunder Bay Regional Cancer Centre. The current complement of four specialists are concurrently involved in the treatment of patients and the training of clerks and residents. At the Juravinski Cancer Centre, division of gynecologic oncology patients have access to national and international clinical trials through the National Cancer Institute of Canada, Princess Margaret Consortium and several pharmaceutical companies. Additionally, the division of gynecologic oncology is involved in the advancement of specific research initiatives and minimally invasive surgery.
RELATED FACULTY
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
Laurie Elit
MD MSc FRCS(C)
Professor Emeritus
Gynecologic Oncology
BIO
Laurie Elit MD MSc FRCS (C) is a professor in the Department of Obstetrics & Gynecology at McMaster University and the division head for gynecologic oncology at Hamilton Health Sciences Centre-Juravinski Cancer Centre. She obtained her medical degree at University of Western Ontario, her fellowship in obstetrics and gynecology at University of Western Ontario, and her gynecologic oncology training at Pennsylvania Hospital, Philadelphia and the University of Toronto. She completed a master’s in health research and methodology at McMaster University. Her research interests involve health services delivery for gynecologic cancer in particular ovarian cancer, treatment decision making with a focus in ovarian cancer and clinical trials with a focus in preinvasive disease. She is the gynecologic disease site team lead for Cancer Care Ontario’s Program in Evidence-Based Care. She has volunteered as an educator, clinician and administrator in several low and middle income settings (i.e., Papua New Guinea, Haiti, Bangladesh, Pakistan, Mongolia, Macedonia). Dr. Elit will be increasing her time commitment to global health endeavors working at Mbingo Baptist Hospital, Cameroon beginning January 2021.
AWARDS
- 2020 Mohide Lectureship, McMaster University, Hamilton
- 2019 Ontario Society of Obstetrics and Gynecology life time achievement award
- 2019 Hamilton Health Sciences Centre Medical Staff Award for Community or Global Humanitarianism
- 2019 Dr. John Mazurka Award for Clinical Surgical Teaching
- 2016 Gynecologic Oncology Canada Presidential Medal
- 2016 Hamilton Health Sciences Centre Medical Staff Association President’s Award for Distinguished Long Service
- 2014 Certificate of Excellence for Sustained and Continuous Pursuit of Excellence in Gynecologic Surgical Training. Department of Obstetrics & Gynecology.
- 2011 American College of Obstetricians and Gynecologists (CREOG) National Faculty Award for Excellence in Resident Education
- 2007 MacKenzie Fellowship in Surgery, Royal College of Physicians and Surgeons Canada
- 2006 Clinical Traineeship Grant from the Royal College of Physicians and Surgeons Canada
RESEARCH INTERESTS
- Health Services Research in Gynecologic Oncology specifically ovarian cancer.
- Randomized trials specifically in CIN 1, PET Scanning for cervical cancer and ovarian cancer.
- Treatment decision making in ovarian cancer.
Research Themes
Ovarian cancer; Cervical cancer; Quality improvement; Screening; Pre-invasive disease
PUBLICATIONS
Francis JA, Elit L, Coakley N, MacKay H And Gynecologic Cancer Disease Site Group. Systematic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Current Oncology. 2017;24(6):e540-e546 doi: 10.3747/co.24.3824
Elit L, Fyles A, Gu C, Pond G, D’Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan T, Gulenchyn K, Metser U, Dhamanaskar K, Levine M. Impact of Positron Emission Tomography (PET) imaging in Women with locally advanced cervical cancer: a Randomized trial. JAMA Open Network 2018:1(5):e182081 doi:10.1001/jamanetworkopen.2018.2081 14Sep2018 pp1-13
Shakeel, S., Elit, L., Akhtar-Danesh, N., Schneider, L. and Finley, C., 2017. Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada, 39(1), pp.25-33.
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Fyles, A., Rakovitch, E., Liu, Y. and Khalifa, M., 2017. The Added Value of Pathology Review in Vulvar Cancer: Results From a Population-based Cohort Study. International Journal of Gynecological Pathology, 36(2), pp.107-110.
McGee, J., Panabaker, K., Leonard, S., Ainsworth, P., Elit, L. and Shariff, S.Z., 2017. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. International Journal of Gynecological Cancer, 27(3), pp.437-443.
Serrano Aybar, P.E., Dhamanaskar, K., Elit, L., Parpia, S., Linkins, L.A., Simunovic, M., Ruo, L., Bhandari, M. and Levine, M.N., 2017. Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. Journal of Clinical Oncology, 35(4) Suppl, pp. 478-478.
Elit, L., 2016. Cervical cancer screening in women over 65. PRO: Are we asking the right question?. Gynecologic Oncology, 142(3), pp.381-382.
Bezanson, K., Nouvet, E., Hunt, M., de Laat, S., Elit, L., Bernard, C. and Schwartz, L., 2016. D08-C The Place of Palliative Care in Humanitarian Response. Journal of Pain and Symptom Management, 52(6), pp.e34-e35.
Mackay, H., Soobrian, J., Murphy, J., Elit, L., Milosevic, M.F., Gollnow, A., Ross, J. and Holloway, C., 2016. Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. Journal of Clinical Oncology, 34(7) Suppl pp. 108-108.
Le, T., Kennedy, E.B., Dodge, J. and Elit, L., 2016. Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation. Current Oncology, 23(5), p.343.
Elit, L., Kennedy, E.B., Fyles, A. and Metser, U., 2016. Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update. Current Oncology, 23(2), p.109.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2016. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access & Health Policy, 4.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Voruganti, T., Moineddin, R., Jembere, N., Elit, L., Grunfeld, E. and Lofters, A.K., 2016. Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ open, 4(3), p.E424.
Elit, L., 2015. Wait times from diagnosis to treatment in cancer. Journal of gynecologic oncology, 26(4), pp.246-248.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?. Pharmacoeconomics, 33(3), pp.235-241.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. The optimal organization of gynecologic oncology services: a systematic review. Current Oncology, 22(4), p.e282.
Elit L, Pond G, Seow H. Letter to the Editor. Wait Time and Survival for Type 1 Endometrial Cancer. Obstetrics and Gynecology 2015:125(6):
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2015. Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecologic oncology, 138(3), pp.536-541.
Elit, L.M., Pond, G. and Seow, H., 2015. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstetrics & Gynecology, 125(6), pp.1497-1498.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. The Silence in Hoch et al.’s Commentary about the Rationale for and Objective (s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. PharmacoEconomics, 33(8), pp.883-886.
Elit, L.M., Fyles, A.W., Gu, C.S., Pond, G.R., D’Souza, D., Samant, R., Anthes, M., Thomas, G., Fillion, M., Arsenault, J. and Dayes, I., 2015. The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. Journal of Clinical Oncology, 33(15) Suppl, pp. 5523-5523.
Murphy, J., Varela, N.P., Elit, L., Lytwyn, A., Yudin, M., Shier, M., Wu, V. and El-Khatib, S., 2015. The organization of colposcopy services in Ontario: recommended framework. Current Oncology, 22(4), p.287.
Elit, L., Charles, C.A. and Gafni, A., 2015. Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. International Journal of Gynecological Cancer, 25(9), pp.1717-1723.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2015. Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer, 25(1), pp.125-130.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. An organizational guideline for gynecologic oncology services. International Journal of Gynecological Cancer, 25(4), pp.551-558.
Elit LM, Charles CA, Gafni A. Oncologists’ perceptions of recurrent ovarian cancer patients’ preference for participation in treatment decision and making and strategies for when and how to involve patients in this process. IJGC, 25(9), 1717-23.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Hirte, H., Kennedy, E.B., Elit, L. and Fung, M.F.K., 2015. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Current Oncology, 22(3), p.211.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2015. Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic oncology, 139(3), pp.465-470.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Prummel, M.V., Young, S.W., Candido, E., Nishri, D., Elit, L. and Marrett, L.D., 2014. Cervical cancer incidence in ontario women: differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell). International Journal of Gynecological Cancer, 24(7), pp.1341-1346.
Tsoref, D., Welch, S., Lau, S., Biagi, J., Tonkin, K., Martin, L.A., Ellard, S., Ghatage, P., Elit, L., Mackay, H.J. and Allo, G., 2014. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 135(2), pp.184-189.
Elit, L., and Hirte, H., 2014. Novel Targeted Therapies in Ovarian Cancer. Journal of Cancer Science and Therapy, 6 pp.350-362.
Elit, L.M., Pond, G. and Seow, H.Y., 2014. Reply to J. Menczer. Journal of Clinical Oncology, 32(19), pp.2114-2114.
Chernesky, M., Jang, D., Gilchrist, J., Elit, L., Lytwyn, A., Smieja, M., Dockter, J., Getman, D., Reid, J. and Hill, C., 2014. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sexually transmitted diseases, 41(6), pp.365-368.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2017. Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic oncology, 144(2), pp.318-323.
Elit, L., 2014. Cervical cancer in the older woman. Maturitas, 78(3), pp.160-167.
Elit, L.M. and Hirte, H., 2014. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert review of anticancer therapy, 14(3), pp.319-332.
Elit, L., 2014. Role of cervical screening in older women. Maturitas, 79(4), pp.413-420.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2014. Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit. Journal of clinical microbiology, 52(2), pp.668-670.
Vicus, D., Sutradhar, R., Lu, Y., Elit, L., Kupets, R., Paszat, L. and Investigators of the Ontario Cancer Screening Research Network, 2014. The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic oncology, 133(2), pp.167-171.
Elit, L.M., O’Leary, E.M., Pond, G.R. and Seow, H.Y., 2013. Impact of wait times on survival for women with uterine cancer. Journal of Clinical Oncology, 32(1), pp.27-33.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2014. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecologic oncology, 134(2), pp.314-318.
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2014. Trends over Time and Regional Variation in the Use of Laparoscopic Hysterectomy for the Treatment of Endometrial Cancer in the Province of Ontario, Canada. Journal of Minimally Invasive Gynecology, 21(6), p.S10.
Hunt M, Schwartz L, Pringle J, Boulanger R, Nouvet E, O’Mathúna D, Arya N, Bernard C, Beukeboom C, Calain P, de Laat S, Eckenwiler L, Elit L, Fraser V, Gillespie LA, Johnson K, Meagher R, Nixon S, Olivier C, Pakes B, Redwood-Campbell L, Reis A, Renaldi T, Singh J, Smith M, Von Schreeb J A research agenda for humanitarian health ethics. PLoS Curr. 12;6
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G.M., Covens, A.L., Elit, L.M., Fyles, A., Rakovitch, E. and Khalifa, M., 2014. Frequency of missing data from vulvar carcinoma pathology reports: Results from a population-based cohort. Gynecologic Oncology, 133, p.192.
Broomfield, J.A., Hirte, H., Elit, L., Kong, I., Patel, M., Voruganti, S., Smith, C., Chow, T. and Swaminath, A., 2014. Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology• Biology• Physics, 90(1), p.S908.
Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A. and Velikova, G., 2013. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The lancet oncology, 14(3), pp.236-243.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Finch, A., Metcalfe, K.A., Chiang, J., Elit, L., McLaughlin, J., Springate, C., Esplen, M.J., Demsky, R., Murphy, J., Rosen, B. and Narod, S.A., 2013. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho-Oncology, 22(1), pp.212-219.
Elit, L., Saskin, R., Raut, R., Elliott, L., Murphy, J. and Marrett, L., 2013. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecologic oncology, 128(1), pp.95-100.
Elit, L. and Hirte, H., 2013. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets Ther, 6, pp.107-18.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2013. Ease and comfort of a new APTIMA specimen collection and transportation kit with cervical and vaginal sampling for Chlamydia trachomatis and Trichomonas vaginalis. Journal of clinical microbiology, pp.JCM-02923.
Elit, L., Charles, C., Gafni, A., Gold, I., Ranford, J. and Gold, S.T., 2013. How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter. Gynecologic Oncology, 130(1), p.e112.
Bell, K., Scott, M., Pond, G., Piccinin, C. and Amer, M., 2013. Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. J Genet Syndr Gene Ther, 4(156), p.2.
Ray-Coquard, I., Haluska, P., O’Reilly, S., Cottu, P.H., Elit, L., Provencher, D.M., Beckmann, M.W., Bosserman, L.D., Jacod, S., Houe, V. and Loberg, R.D., 2013. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 31(15) Suppl, pp. 5515-5515.
Murphy, K.J., Elit, L., 2013. Cervical screening guidelines — discordance discussed [eletter]. CMAJ; 2013 Mar. 22.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N., de Laat, S., and Ranford, J., 2013. La déontologie des activités cliniques occidentales est-elle applicable aux contextes humanitaires a l’étranger?. In: Abu-Sada C, ed. Jeux de miroir: Réflexions sur MSF et l’action humanitaire. Lausanne, Switzerland: Antipodes:77-92.
Lewis, G.H., DeScipio, C., Murphy, K.M., Haley, L., Beierl, K., Mosier, S., Tandy, S., Cohen, D.S., Lytwyn, A., Elit, L. and Vang, R., 2013. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. International Journal of Gynecological Pathology, 32(2), pp.199-214.
O’Leary, E., Elit, L., Pond, G. and Seow, H., 2013. The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic oncology, 131(1), pp.151-157.
Goodwin, R.A., Jamal, R., Tu, D., Walsh, W., Dancey, J., Oza, A.M., Elit, L. and Eisenhauer, E.A., 2013. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 131(2), pp.315-320.
Elit, L., Charles, C., Gafni, A., Ranford, J., Gold, S.T. and Gold, I., 2012. Walking a tightrope: oncologists’ perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer, 20(10), pp.2327-2333.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eva Grunfeld, Rahim Moineddin, Nadia Gunraj M. Elisabeth del Giudice, David C. Hodgson, Janice Kwon, Laurie Elit. A population based longitudinal study of cancer screening practices of cancer survivors. Canadian Family Physician 2012;58(9);980-6
Elit L, Lee A, Swynstun L, Liaw P, Julian J, Hoskins P, Parpeer S, Julian D, Levine M. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research 2012, 130(6)894-900
Jason E. Dodge, Allan L. Covens, Christina Lacchetti, Laurie M. Elit, Tien Le, Michaela Devries-Aboud, Michael Fung Kee Fung and The Gynecologic Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gyn Onc 2012;126:157-166
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Ginsburg, O.M., Hanna, T.P., Vandenberg, T., Joy, A.A., Clemons, M., Game, M., MacCormick, R., Elit, L.M., Rosen, B., Rahim, Y. and Geddie, W., 2012. The global cancer epidemic: opportunities for Canada in low-and middle-income countries. Canadian Medical Association Journal, 184(15), pp.1699-1704.
Elit, L., Lytwyn, A. and Akhtar-Danesh, N., 2012. Long-Term Trends in the Survival of Women with Endometrial Cancer in Canada: A Population-Based Study. Journal of Cancer Therapy, 3(05), p.853.
Kollmannsberger C, Hirte H , Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Chen H, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A NCIC-CTG phase I, open-label, dose escalation study (IND 179) Annals of Oncology 2012;23(1);238-44
Elit, L.M., Lee, A.Y., Parpia, S., Swystun, L.L., Liaw, P.C., Hoskins, P., Julian, D.H., Julian, J.A. and Levine, M.N., 2012. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis research, 130(6), pp.894-900.
Grunfeld, E., Moineddin, R., Gunraj, N., Del Giudice, M.E., Hodgson, D.C., Kwon, J.S. and Elit, L., 2012. Cancer screening practices of cancer survivors Population-based, longitudinal study. Canadian Family Physician, 58(9), pp.980-986.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N. and de Laat, S., 2012. Models for humanitarian health care ethics. Public Health Ethics, 5(1), pp.81-90.
Lawson, L., Lytwyn, A., Jang, D., Howard, M., Elit, L., Onuma, K., Klingel, M., Toor, R., Gilchrist, J., Ecobichon-Morris, A. and Smieja, M., 2012. Comparison of APTIMA HPV E6/E7 mRNA and Hybrid Capture 2 assays using wet and dry self-collected flocked vaginal swabs and PreservCyt L-Pap samples. Journal of Analytical Oncology, 1(2), pp.149-154.
Hunt, M.R., Schwartz, L., Sinding, C. and Elit, L., 2014. The ethics of engaged presence: a framework for health professionals in humanitarian assistance and development work. Developing world bioethics, 14(1), pp.47-55.
Hunt, M.R., Schwartz, L. and Elit, L., 2012. Experience of ethics training and support for health care professionals in international aid work. Public Health Ethics, 5(1), pp.91-99.
Akhtar-Danesh, N., Lytwyn, A. and Elit, L., 2012. Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecologic oncology, 127(3), pp.620-624.
Dodge, J.E., Covens, A.L., Lacchetti, C., Elit, L.M., Le, T., Devries–Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Management of a suspicious adnexal mass: a clinical practice guideline. Current oncology, 19(4), p.e244.
Trim, K., Nagji, N., Elit, L. and Roy, K., 2012. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstetrics and gynecology international, 2012.
Elit, L., Krzyzanowska, M., Saskin, R., Barbera, L., Razzaq, A., Lofters, A., Yeritsyan, N. and Bierman, A., 2012. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Canadian Family Physician, 58(1), pp.e22-e31.
Covens, A.L., Dodge, J.E., Lacchetti, C., Elit, L.M., Le, T., Devries-Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Surgical management of a suspicious adnexal mass: a systematic review. Gynecologic oncology, 126(1), pp.149-156.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2012. Temporal trends in the relative survival among women with cervical cancer in Canada: a population-based study. International Journal of Gynecological Cancer, 22(7), pp.1208-1213.
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S. and Helland, H., 2012. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of oncology, 23(5), pp.1185-1189.
Laurie Elit
MD MSc FRCS(C)
Professor Emeritus
Gynecologic Oncology
Waldo Jimenez
MD
Associate Professor
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Waldo Jimenez
MD
Associate Professor
Gynecologic Oncology
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Laurie Elit
MD MSc FRCS(C)
Professor Emeritus
Gynecologic Oncology
BIO
Laurie Elit MD MSc FRCS (C) is a professor in the Department of Obstetrics & Gynecology at McMaster University and the division head for gynecologic oncology at Hamilton Health Sciences Centre-Juravinski Cancer Centre. She obtained her medical degree at University of Western Ontario, her fellowship in obstetrics and gynecology at University of Western Ontario, and her gynecologic oncology training at Pennsylvania Hospital, Philadelphia and the University of Toronto. She completed a master’s in health research and methodology at McMaster University. Her research interests involve health services delivery for gynecologic cancer in particular ovarian cancer, treatment decision making with a focus in ovarian cancer and clinical trials with a focus in preinvasive disease. She is the gynecologic disease site team lead for Cancer Care Ontario’s Program in Evidence-Based Care. She has volunteered as an educator, clinician and administrator in several low and middle income settings (i.e., Papua New Guinea, Haiti, Bangladesh, Pakistan, Mongolia, Macedonia). Dr. Elit will be increasing her time commitment to global health endeavors working at Mbingo Baptist Hospital, Cameroon beginning January 2021.
AWARDS
- 2020 Mohide Lectureship, McMaster University, Hamilton
- 2019 Ontario Society of Obstetrics and Gynecology life time achievement award
- 2019 Hamilton Health Sciences Centre Medical Staff Award for Community or Global Humanitarianism
- 2019 Dr. John Mazurka Award for Clinical Surgical Teaching
- 2016 Gynecologic Oncology Canada Presidential Medal
- 2016 Hamilton Health Sciences Centre Medical Staff Association President’s Award for Distinguished Long Service
- 2014 Certificate of Excellence for Sustained and Continuous Pursuit of Excellence in Gynecologic Surgical Training. Department of Obstetrics & Gynecology.
- 2011 American College of Obstetricians and Gynecologists (CREOG) National Faculty Award for Excellence in Resident Education
- 2007 MacKenzie Fellowship in Surgery, Royal College of Physicians and Surgeons Canada
- 2006 Clinical Traineeship Grant from the Royal College of Physicians and Surgeons Canada
RESEARCH INTERESTS
- Health Services Research in Gynecologic Oncology specifically ovarian cancer.
- Randomized trials specifically in CIN 1, PET Scanning for cervical cancer and ovarian cancer.
- Treatment decision making in ovarian cancer.
Research Themes
Ovarian cancer; Cervical cancer; Quality improvement; Screening; Pre-invasive disease
PUBLICATIONS
Francis JA, Elit L, Coakley N, MacKay H And Gynecologic Cancer Disease Site Group. Systematic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Current Oncology. 2017;24(6):e540-e546 doi: 10.3747/co.24.3824
Elit L, Fyles A, Gu C, Pond G, D’Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan T, Gulenchyn K, Metser U, Dhamanaskar K, Levine M. Impact of Positron Emission Tomography (PET) imaging in Women with locally advanced cervical cancer: a Randomized trial. JAMA Open Network 2018:1(5):e182081 doi:10.1001/jamanetworkopen.2018.2081 14Sep2018 pp1-13
Shakeel, S., Elit, L., Akhtar-Danesh, N., Schneider, L. and Finley, C., 2017. Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada, 39(1), pp.25-33.
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Fyles, A., Rakovitch, E., Liu, Y. and Khalifa, M., 2017. The Added Value of Pathology Review in Vulvar Cancer: Results From a Population-based Cohort Study. International Journal of Gynecological Pathology, 36(2), pp.107-110.
McGee, J., Panabaker, K., Leonard, S., Ainsworth, P., Elit, L. and Shariff, S.Z., 2017. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. International Journal of Gynecological Cancer, 27(3), pp.437-443.
Serrano Aybar, P.E., Dhamanaskar, K., Elit, L., Parpia, S., Linkins, L.A., Simunovic, M., Ruo, L., Bhandari, M. and Levine, M.N., 2017. Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. Journal of Clinical Oncology, 35(4) Suppl, pp. 478-478.
Elit, L., 2016. Cervical cancer screening in women over 65. PRO: Are we asking the right question?. Gynecologic Oncology, 142(3), pp.381-382.
Bezanson, K., Nouvet, E., Hunt, M., de Laat, S., Elit, L., Bernard, C. and Schwartz, L., 2016. D08-C The Place of Palliative Care in Humanitarian Response. Journal of Pain and Symptom Management, 52(6), pp.e34-e35.
Mackay, H., Soobrian, J., Murphy, J., Elit, L., Milosevic, M.F., Gollnow, A., Ross, J. and Holloway, C., 2016. Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. Journal of Clinical Oncology, 34(7) Suppl pp. 108-108.
Le, T., Kennedy, E.B., Dodge, J. and Elit, L., 2016. Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation. Current Oncology, 23(5), p.343.
Elit, L., Kennedy, E.B., Fyles, A. and Metser, U., 2016. Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update. Current Oncology, 23(2), p.109.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2016. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access & Health Policy, 4.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Voruganti, T., Moineddin, R., Jembere, N., Elit, L., Grunfeld, E. and Lofters, A.K., 2016. Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ open, 4(3), p.E424.
Elit, L., 2015. Wait times from diagnosis to treatment in cancer. Journal of gynecologic oncology, 26(4), pp.246-248.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?. Pharmacoeconomics, 33(3), pp.235-241.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. The optimal organization of gynecologic oncology services: a systematic review. Current Oncology, 22(4), p.e282.
Elit L, Pond G, Seow H. Letter to the Editor. Wait Time and Survival for Type 1 Endometrial Cancer. Obstetrics and Gynecology 2015:125(6):
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2015. Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecologic oncology, 138(3), pp.536-541.
Elit, L.M., Pond, G. and Seow, H., 2015. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstetrics & Gynecology, 125(6), pp.1497-1498.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. The Silence in Hoch et al.’s Commentary about the Rationale for and Objective (s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. PharmacoEconomics, 33(8), pp.883-886.
Elit, L.M., Fyles, A.W., Gu, C.S., Pond, G.R., D’Souza, D., Samant, R., Anthes, M., Thomas, G., Fillion, M., Arsenault, J. and Dayes, I., 2015. The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. Journal of Clinical Oncology, 33(15) Suppl, pp. 5523-5523.
Murphy, J., Varela, N.P., Elit, L., Lytwyn, A., Yudin, M., Shier, M., Wu, V. and El-Khatib, S., 2015. The organization of colposcopy services in Ontario: recommended framework. Current Oncology, 22(4), p.287.
Elit, L., Charles, C.A. and Gafni, A., 2015. Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. International Journal of Gynecological Cancer, 25(9), pp.1717-1723.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2015. Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer, 25(1), pp.125-130.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. An organizational guideline for gynecologic oncology services. International Journal of Gynecological Cancer, 25(4), pp.551-558.
Elit LM, Charles CA, Gafni A. Oncologists’ perceptions of recurrent ovarian cancer patients’ preference for participation in treatment decision and making and strategies for when and how to involve patients in this process. IJGC, 25(9), 1717-23.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Hirte, H., Kennedy, E.B., Elit, L. and Fung, M.F.K., 2015. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Current Oncology, 22(3), p.211.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2015. Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic oncology, 139(3), pp.465-470.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Prummel, M.V., Young, S.W., Candido, E., Nishri, D., Elit, L. and Marrett, L.D., 2014. Cervical cancer incidence in ontario women: differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell). International Journal of Gynecological Cancer, 24(7), pp.1341-1346.
Tsoref, D., Welch, S., Lau, S., Biagi, J., Tonkin, K., Martin, L.A., Ellard, S., Ghatage, P., Elit, L., Mackay, H.J. and Allo, G., 2014. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 135(2), pp.184-189.
Elit, L., and Hirte, H., 2014. Novel Targeted Therapies in Ovarian Cancer. Journal of Cancer Science and Therapy, 6 pp.350-362.
Elit, L.M., Pond, G. and Seow, H.Y., 2014. Reply to J. Menczer. Journal of Clinical Oncology, 32(19), pp.2114-2114.
Chernesky, M., Jang, D., Gilchrist, J., Elit, L., Lytwyn, A., Smieja, M., Dockter, J., Getman, D., Reid, J. and Hill, C., 2014. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sexually transmitted diseases, 41(6), pp.365-368.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2017. Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic oncology, 144(2), pp.318-323.
Elit, L., 2014. Cervical cancer in the older woman. Maturitas, 78(3), pp.160-167.
Elit, L.M. and Hirte, H., 2014. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert review of anticancer therapy, 14(3), pp.319-332.
Elit, L., 2014. Role of cervical screening in older women. Maturitas, 79(4), pp.413-420.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2014. Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit. Journal of clinical microbiology, 52(2), pp.668-670.
Vicus, D., Sutradhar, R., Lu, Y., Elit, L., Kupets, R., Paszat, L. and Investigators of the Ontario Cancer Screening Research Network, 2014. The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic oncology, 133(2), pp.167-171.
Elit, L.M., O’Leary, E.M., Pond, G.R. and Seow, H.Y., 2013. Impact of wait times on survival for women with uterine cancer. Journal of Clinical Oncology, 32(1), pp.27-33.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2014. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecologic oncology, 134(2), pp.314-318.
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2014. Trends over Time and Regional Variation in the Use of Laparoscopic Hysterectomy for the Treatment of Endometrial Cancer in the Province of Ontario, Canada. Journal of Minimally Invasive Gynecology, 21(6), p.S10.
Hunt M, Schwartz L, Pringle J, Boulanger R, Nouvet E, O’Mathúna D, Arya N, Bernard C, Beukeboom C, Calain P, de Laat S, Eckenwiler L, Elit L, Fraser V, Gillespie LA, Johnson K, Meagher R, Nixon S, Olivier C, Pakes B, Redwood-Campbell L, Reis A, Renaldi T, Singh J, Smith M, Von Schreeb J A research agenda for humanitarian health ethics. PLoS Curr. 12;6
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G.M., Covens, A.L., Elit, L.M., Fyles, A., Rakovitch, E. and Khalifa, M., 2014. Frequency of missing data from vulvar carcinoma pathology reports: Results from a population-based cohort. Gynecologic Oncology, 133, p.192.
Broomfield, J.A., Hirte, H., Elit, L., Kong, I., Patel, M., Voruganti, S., Smith, C., Chow, T. and Swaminath, A., 2014. Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology• Biology• Physics, 90(1), p.S908.
Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A. and Velikova, G., 2013. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The lancet oncology, 14(3), pp.236-243.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Finch, A., Metcalfe, K.A., Chiang, J., Elit, L., McLaughlin, J., Springate, C., Esplen, M.J., Demsky, R., Murphy, J., Rosen, B. and Narod, S.A., 2013. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho-Oncology, 22(1), pp.212-219.
Elit, L., Saskin, R., Raut, R., Elliott, L., Murphy, J. and Marrett, L., 2013. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecologic oncology, 128(1), pp.95-100.
Elit, L. and Hirte, H., 2013. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets Ther, 6, pp.107-18.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2013. Ease and comfort of a new APTIMA specimen collection and transportation kit with cervical and vaginal sampling for Chlamydia trachomatis and Trichomonas vaginalis. Journal of clinical microbiology, pp.JCM-02923.
Elit, L., Charles, C., Gafni, A., Gold, I., Ranford, J. and Gold, S.T., 2013. How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter. Gynecologic Oncology, 130(1), p.e112.
Bell, K., Scott, M., Pond, G., Piccinin, C. and Amer, M., 2013. Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. J Genet Syndr Gene Ther, 4(156), p.2.
Ray-Coquard, I., Haluska, P., O’Reilly, S., Cottu, P.H., Elit, L., Provencher, D.M., Beckmann, M.W., Bosserman, L.D., Jacod, S., Houe, V. and Loberg, R.D., 2013. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 31(15) Suppl, pp. 5515-5515.
Murphy, K.J., Elit, L., 2013. Cervical screening guidelines — discordance discussed [eletter]. CMAJ; 2013 Mar. 22.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N., de Laat, S., and Ranford, J., 2013. La déontologie des activités cliniques occidentales est-elle applicable aux contextes humanitaires a l’étranger?. In: Abu-Sada C, ed. Jeux de miroir: Réflexions sur MSF et l’action humanitaire. Lausanne, Switzerland: Antipodes:77-92.
Lewis, G.H., DeScipio, C., Murphy, K.M., Haley, L., Beierl, K., Mosier, S., Tandy, S., Cohen, D.S., Lytwyn, A., Elit, L. and Vang, R., 2013. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. International Journal of Gynecological Pathology, 32(2), pp.199-214.
O’Leary, E., Elit, L., Pond, G. and Seow, H., 2013. The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic oncology, 131(1), pp.151-157.
Goodwin, R.A., Jamal, R., Tu, D., Walsh, W., Dancey, J., Oza, A.M., Elit, L. and Eisenhauer, E.A., 2013. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 131(2), pp.315-320.
Elit, L., Charles, C., Gafni, A., Ranford, J., Gold, S.T. and Gold, I., 2012. Walking a tightrope: oncologists’ perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer, 20(10), pp.2327-2333.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eva Grunfeld, Rahim Moineddin, Nadia Gunraj M. Elisabeth del Giudice, David C. Hodgson, Janice Kwon, Laurie Elit. A population based longitudinal study of cancer screening practices of cancer survivors. Canadian Family Physician 2012;58(9);980-6
Elit L, Lee A, Swynstun L, Liaw P, Julian J, Hoskins P, Parpeer S, Julian D, Levine M. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research 2012, 130(6)894-900
Jason E. Dodge, Allan L. Covens, Christina Lacchetti, Laurie M. Elit, Tien Le, Michaela Devries-Aboud, Michael Fung Kee Fung and The Gynecologic Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gyn Onc 2012;126:157-166
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Ginsburg, O.M., Hanna, T.P., Vandenberg, T., Joy, A.A., Clemons, M., Game, M., MacCormick, R., Elit, L.M., Rosen, B., Rahim, Y. and Geddie, W., 2012. The global cancer epidemic: opportunities for Canada in low-and middle-income countries. Canadian Medical Association Journal, 184(15), pp.1699-1704.
Elit, L., Lytwyn, A. and Akhtar-Danesh, N., 2012. Long-Term Trends in the Survival of Women with Endometrial Cancer in Canada: A Population-Based Study. Journal of Cancer Therapy, 3(05), p.853.
Kollmannsberger C, Hirte H , Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Chen H, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A NCIC-CTG phase I, open-label, dose escalation study (IND 179) Annals of Oncology 2012;23(1);238-44
Elit, L.M., Lee, A.Y., Parpia, S., Swystun, L.L., Liaw, P.C., Hoskins, P., Julian, D.H., Julian, J.A. and Levine, M.N., 2012. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis research, 130(6), pp.894-900.
Grunfeld, E., Moineddin, R., Gunraj, N., Del Giudice, M.E., Hodgson, D.C., Kwon, J.S. and Elit, L., 2012. Cancer screening practices of cancer survivors Population-based, longitudinal study. Canadian Family Physician, 58(9), pp.980-986.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N. and de Laat, S., 2012. Models for humanitarian health care ethics. Public Health Ethics, 5(1), pp.81-90.
Lawson, L., Lytwyn, A., Jang, D., Howard, M., Elit, L., Onuma, K., Klingel, M., Toor, R., Gilchrist, J., Ecobichon-Morris, A. and Smieja, M., 2012. Comparison of APTIMA HPV E6/E7 mRNA and Hybrid Capture 2 assays using wet and dry self-collected flocked vaginal swabs and PreservCyt L-Pap samples. Journal of Analytical Oncology, 1(2), pp.149-154.
Hunt, M.R., Schwartz, L., Sinding, C. and Elit, L., 2014. The ethics of engaged presence: a framework for health professionals in humanitarian assistance and development work. Developing world bioethics, 14(1), pp.47-55.
Hunt, M.R., Schwartz, L. and Elit, L., 2012. Experience of ethics training and support for health care professionals in international aid work. Public Health Ethics, 5(1), pp.91-99.
Akhtar-Danesh, N., Lytwyn, A. and Elit, L., 2012. Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecologic oncology, 127(3), pp.620-624.
Dodge, J.E., Covens, A.L., Lacchetti, C., Elit, L.M., Le, T., Devries–Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Management of a suspicious adnexal mass: a clinical practice guideline. Current oncology, 19(4), p.e244.
Trim, K., Nagji, N., Elit, L. and Roy, K., 2012. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstetrics and gynecology international, 2012.
Elit, L., Krzyzanowska, M., Saskin, R., Barbera, L., Razzaq, A., Lofters, A., Yeritsyan, N. and Bierman, A., 2012. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Canadian Family Physician, 58(1), pp.e22-e31.
Covens, A.L., Dodge, J.E., Lacchetti, C., Elit, L.M., Le, T., Devries-Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Surgical management of a suspicious adnexal mass: a systematic review. Gynecologic oncology, 126(1), pp.149-156.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2012. Temporal trends in the relative survival among women with cervical cancer in Canada: a population-based study. International Journal of Gynecological Cancer, 22(7), pp.1208-1213.
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S. and Helland, H., 2012. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of oncology, 23(5), pp.1185-1189.
Laurie Elit
MD MSc FRCS(C)
Professor Emeritus
Gynecologic Oncology
BIO
Laurie Elit MD MSc FRCS (C) is a professor in the Department of Obstetrics & Gynecology at McMaster University and the division head for gynecologic oncology at Hamilton Health Sciences Centre-Juravinski Cancer Centre. She obtained her medical degree at University of Western Ontario, her fellowship in obstetrics and gynecology at University of Western Ontario, and her gynecologic oncology training at Pennsylvania Hospital, Philadelphia and the University of Toronto. She completed a master’s in health research and methodology at McMaster University. Her research interests involve health services delivery for gynecologic cancer in particular ovarian cancer, treatment decision making with a focus in ovarian cancer and clinical trials with a focus in preinvasive disease. She is the gynecologic disease site team lead for Cancer Care Ontario’s Program in Evidence-Based Care. She has volunteered as an educator, clinician and administrator in several low and middle income settings (i.e., Papua New Guinea, Haiti, Bangladesh, Pakistan, Mongolia, Macedonia). Dr. Elit will be increasing her time commitment to global health endeavors working at Mbingo Baptist Hospital, Cameroon beginning January 2021.
AWARDS
- 2020 Mohide Lectureship, McMaster University, Hamilton
- 2019 Ontario Society of Obstetrics and Gynecology life time achievement award
- 2019 Hamilton Health Sciences Centre Medical Staff Award for Community or Global Humanitarianism
- 2019 Dr. John Mazurka Award for Clinical Surgical Teaching
- 2016 Gynecologic Oncology Canada Presidential Medal
- 2016 Hamilton Health Sciences Centre Medical Staff Association President’s Award for Distinguished Long Service
- 2014 Certificate of Excellence for Sustained and Continuous Pursuit of Excellence in Gynecologic Surgical Training. Department of Obstetrics & Gynecology.
- 2011 American College of Obstetricians and Gynecologists (CREOG) National Faculty Award for Excellence in Resident Education
- 2007 MacKenzie Fellowship in Surgery, Royal College of Physicians and Surgeons Canada
- 2006 Clinical Traineeship Grant from the Royal College of Physicians and Surgeons Canada
RESEARCH INTERESTS
- Health Services Research in Gynecologic Oncology specifically ovarian cancer.
- Randomized trials specifically in CIN 1, PET Scanning for cervical cancer and ovarian cancer.
- Treatment decision making in ovarian cancer.
Research Themes
Ovarian cancer; Cervical cancer; Quality improvement; Screening; Pre-invasive disease
PUBLICATIONS
Francis JA, Elit L, Coakley N, MacKay H And Gynecologic Cancer Disease Site Group. Systematic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Current Oncology. 2017;24(6):e540-e546 doi: 10.3747/co.24.3824
Elit L, Fyles A, Gu C, Pond G, D’Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan T, Gulenchyn K, Metser U, Dhamanaskar K, Levine M. Impact of Positron Emission Tomography (PET) imaging in Women with locally advanced cervical cancer: a Randomized trial. JAMA Open Network 2018:1(5):e182081 doi:10.1001/jamanetworkopen.2018.2081 14Sep2018 pp1-13
Shakeel, S., Elit, L., Akhtar-Danesh, N., Schneider, L. and Finley, C., 2017. Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada, 39(1), pp.25-33.
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Fyles, A., Rakovitch, E., Liu, Y. and Khalifa, M., 2017. The Added Value of Pathology Review in Vulvar Cancer: Results From a Population-based Cohort Study. International Journal of Gynecological Pathology, 36(2), pp.107-110.
McGee, J., Panabaker, K., Leonard, S., Ainsworth, P., Elit, L. and Shariff, S.Z., 2017. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. International Journal of Gynecological Cancer, 27(3), pp.437-443.
Serrano Aybar, P.E., Dhamanaskar, K., Elit, L., Parpia, S., Linkins, L.A., Simunovic, M., Ruo, L., Bhandari, M. and Levine, M.N., 2017. Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. Journal of Clinical Oncology, 35(4) Suppl, pp. 478-478.
Elit, L., 2016. Cervical cancer screening in women over 65. PRO: Are we asking the right question?. Gynecologic Oncology, 142(3), pp.381-382.
Bezanson, K., Nouvet, E., Hunt, M., de Laat, S., Elit, L., Bernard, C. and Schwartz, L., 2016. D08-C The Place of Palliative Care in Humanitarian Response. Journal of Pain and Symptom Management, 52(6), pp.e34-e35.
Mackay, H., Soobrian, J., Murphy, J., Elit, L., Milosevic, M.F., Gollnow, A., Ross, J. and Holloway, C., 2016. Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. Journal of Clinical Oncology, 34(7) Suppl pp. 108-108.
Le, T., Kennedy, E.B., Dodge, J. and Elit, L., 2016. Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation. Current Oncology, 23(5), p.343.
Elit, L., Kennedy, E.B., Fyles, A. and Metser, U., 2016. Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update. Current Oncology, 23(2), p.109.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2016. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access & Health Policy, 4.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Voruganti, T., Moineddin, R., Jembere, N., Elit, L., Grunfeld, E. and Lofters, A.K., 2016. Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ open, 4(3), p.E424.
Elit, L., 2015. Wait times from diagnosis to treatment in cancer. Journal of gynecologic oncology, 26(4), pp.246-248.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?. Pharmacoeconomics, 33(3), pp.235-241.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. The optimal organization of gynecologic oncology services: a systematic review. Current Oncology, 22(4), p.e282.
Elit L, Pond G, Seow H. Letter to the Editor. Wait Time and Survival for Type 1 Endometrial Cancer. Obstetrics and Gynecology 2015:125(6):
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2015. Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecologic oncology, 138(3), pp.536-541.
Elit, L.M., Pond, G. and Seow, H., 2015. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstetrics & Gynecology, 125(6), pp.1497-1498.
McDonald, H., Charles, C., Elit, L. and Gafni, A., 2015. The Silence in Hoch et al.’s Commentary about the Rationale for and Objective (s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. PharmacoEconomics, 33(8), pp.883-886.
Elit, L.M., Fyles, A.W., Gu, C.S., Pond, G.R., D’Souza, D., Samant, R., Anthes, M., Thomas, G., Fillion, M., Arsenault, J. and Dayes, I., 2015. The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. Journal of Clinical Oncology, 33(15) Suppl, pp. 5523-5523.
Murphy, J., Varela, N.P., Elit, L., Lytwyn, A., Yudin, M., Shier, M., Wu, V. and El-Khatib, S., 2015. The organization of colposcopy services in Ontario: recommended framework. Current Oncology, 22(4), p.287.
Elit, L., Charles, C.A. and Gafni, A., 2015. Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. International Journal of Gynecological Cancer, 25(9), pp.1717-1723.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2015. Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer, 25(1), pp.125-130.
Fung-Kee-Fung, M., Kennedy, E.B., Biagi, J., Colgan, T., D’Souza, D., Elit, L.M., Hunter, A., Irish, J., McLeod, R. and Rosen, B., 2015. An organizational guideline for gynecologic oncology services. International Journal of Gynecological Cancer, 25(4), pp.551-558.
Elit LM, Charles CA, Gafni A. Oncologists’ perceptions of recurrent ovarian cancer patients’ preference for participation in treatment decision and making and strategies for when and how to involve patients in this process. IJGC, 25(9), 1717-23.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Hirte, H., Kennedy, E.B., Elit, L. and Fung, M.F.K., 2015. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Current Oncology, 22(3), p.211.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2015. Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic oncology, 139(3), pp.465-470.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Prummel, M.V., Young, S.W., Candido, E., Nishri, D., Elit, L. and Marrett, L.D., 2014. Cervical cancer incidence in ontario women: differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell). International Journal of Gynecological Cancer, 24(7), pp.1341-1346.
Tsoref, D., Welch, S., Lau, S., Biagi, J., Tonkin, K., Martin, L.A., Ellard, S., Ghatage, P., Elit, L., Mackay, H.J. and Allo, G., 2014. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 135(2), pp.184-189.
Elit, L., and Hirte, H., 2014. Novel Targeted Therapies in Ovarian Cancer. Journal of Cancer Science and Therapy, 6 pp.350-362.
Elit, L.M., Pond, G. and Seow, H.Y., 2014. Reply to J. Menczer. Journal of Clinical Oncology, 32(19), pp.2114-2114.
Chernesky, M., Jang, D., Gilchrist, J., Elit, L., Lytwyn, A., Smieja, M., Dockter, J., Getman, D., Reid, J. and Hill, C., 2014. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sexually transmitted diseases, 41(6), pp.365-368.
Gien, L.T., Sutradhar, R., Thomas, G., Covens, A., Elit, L., Rakovitch, E., Fyles, A., Khalifa, M.A., Liu, Y. and Barbera, L., 2017. Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic oncology, 144(2), pp.318-323.
Elit, L., 2014. Cervical cancer in the older woman. Maturitas, 78(3), pp.160-167.
Elit, L.M. and Hirte, H., 2014. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert review of anticancer therapy, 14(3), pp.319-332.
Elit, L., 2014. Role of cervical screening in older women. Maturitas, 79(4), pp.413-420.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2014. Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit. Journal of clinical microbiology, 52(2), pp.668-670.
Vicus, D., Sutradhar, R., Lu, Y., Elit, L., Kupets, R., Paszat, L. and Investigators of the Ontario Cancer Screening Research Network, 2014. The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic oncology, 133(2), pp.167-171.
Elit, L.M., O’Leary, E.M., Pond, G.R. and Seow, H.Y., 2013. Impact of wait times on survival for women with uterine cancer. Journal of Clinical Oncology, 32(1), pp.27-33.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2014. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecologic oncology, 134(2), pp.314-318.
Kroft, J., Li, Q., Saskin, R., Elit, L., Bernardini, M.Q. and Gien, L.T., 2014. Trends over Time and Regional Variation in the Use of Laparoscopic Hysterectomy for the Treatment of Endometrial Cancer in the Province of Ontario, Canada. Journal of Minimally Invasive Gynecology, 21(6), p.S10.
Hunt M, Schwartz L, Pringle J, Boulanger R, Nouvet E, O’Mathúna D, Arya N, Bernard C, Beukeboom C, Calain P, de Laat S, Eckenwiler L, Elit L, Fraser V, Gillespie LA, Johnson K, Meagher R, Nixon S, Olivier C, Pakes B, Redwood-Campbell L, Reis A, Renaldi T, Singh J, Smith M, Von Schreeb J A research agenda for humanitarian health ethics. PLoS Curr. 12;6
Barbera, L., Gien, L.T., Sutradhar, R., Thomas, G.M., Covens, A.L., Elit, L.M., Fyles, A., Rakovitch, E. and Khalifa, M., 2014. Frequency of missing data from vulvar carcinoma pathology reports: Results from a population-based cohort. Gynecologic Oncology, 133, p.192.
Broomfield, J.A., Hirte, H., Elit, L., Kong, I., Patel, M., Voruganti, S., Smith, C., Chow, T. and Swaminath, A., 2014. Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology• Biology• Physics, 90(1), p.S908.
Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A. and Velikova, G., 2013. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The lancet oncology, 14(3), pp.236-243.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Finch, A., Metcalfe, K.A., Chiang, J., Elit, L., McLaughlin, J., Springate, C., Esplen, M.J., Demsky, R., Murphy, J., Rosen, B. and Narod, S.A., 2013. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho-Oncology, 22(1), pp.212-219.
Elit, L., Saskin, R., Raut, R., Elliott, L., Murphy, J. and Marrett, L., 2013. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecologic oncology, 128(1), pp.95-100.
Elit, L. and Hirte, H., 2013. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets Ther, 6, pp.107-18.
Chernesky, M., Jang, D., Gilchrist, J., Randazzo, J., Elit, L., Lytwyn, A., Smieja, M., Reid, J. and Hill, C., 2013. Ease and comfort of a new APTIMA specimen collection and transportation kit with cervical and vaginal sampling for Chlamydia trachomatis and Trichomonas vaginalis. Journal of clinical microbiology, pp.JCM-02923.
Elit, L., Charles, C., Gafni, A., Gold, I., Ranford, J. and Gold, S.T., 2013. How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter. Gynecologic Oncology, 130(1), p.e112.
Bell, K., Scott, M., Pond, G., Piccinin, C. and Amer, M., 2013. Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. J Genet Syndr Gene Ther, 4(156), p.2.
Ray-Coquard, I., Haluska, P., O’Reilly, S., Cottu, P.H., Elit, L., Provencher, D.M., Beckmann, M.W., Bosserman, L.D., Jacod, S., Houe, V. and Loberg, R.D., 2013. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 31(15) Suppl, pp. 5515-5515.
Murphy, K.J., Elit, L., 2013. Cervical screening guidelines — discordance discussed [eletter]. CMAJ; 2013 Mar. 22.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N., de Laat, S., and Ranford, J., 2013. La déontologie des activités cliniques occidentales est-elle applicable aux contextes humanitaires a l’étranger?. In: Abu-Sada C, ed. Jeux de miroir: Réflexions sur MSF et l’action humanitaire. Lausanne, Switzerland: Antipodes:77-92.
Lewis, G.H., DeScipio, C., Murphy, K.M., Haley, L., Beierl, K., Mosier, S., Tandy, S., Cohen, D.S., Lytwyn, A., Elit, L. and Vang, R., 2013. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. International Journal of Gynecological Pathology, 32(2), pp.199-214.
O’Leary, E., Elit, L., Pond, G. and Seow, H., 2013. The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic oncology, 131(1), pp.151-157.
Goodwin, R.A., Jamal, R., Tu, D., Walsh, W., Dancey, J., Oza, A.M., Elit, L. and Eisenhauer, E.A., 2013. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic oncology, 131(2), pp.315-320.
Elit, L., Charles, C., Gafni, A., Ranford, J., Gold, S.T. and Gold, I., 2012. Walking a tightrope: oncologists’ perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer, 20(10), pp.2327-2333.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Eva Grunfeld, Rahim Moineddin, Nadia Gunraj M. Elisabeth del Giudice, David C. Hodgson, Janice Kwon, Laurie Elit. A population based longitudinal study of cancer screening practices of cancer survivors. Canadian Family Physician 2012;58(9);980-6
Elit L, Lee A, Swynstun L, Liaw P, Julian J, Hoskins P, Parpeer S, Julian D, Levine M. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research 2012, 130(6)894-900
Jason E. Dodge, Allan L. Covens, Christina Lacchetti, Laurie M. Elit, Tien Le, Michaela Devries-Aboud, Michael Fung Kee Fung and The Gynecologic Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gyn Onc 2012;126:157-166
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Ginsburg, O.M., Hanna, T.P., Vandenberg, T., Joy, A.A., Clemons, M., Game, M., MacCormick, R., Elit, L.M., Rosen, B., Rahim, Y. and Geddie, W., 2012. The global cancer epidemic: opportunities for Canada in low-and middle-income countries. Canadian Medical Association Journal, 184(15), pp.1699-1704.
Elit, L., Lytwyn, A. and Akhtar-Danesh, N., 2012. Long-Term Trends in the Survival of Women with Endometrial Cancer in Canada: A Population-Based Study. Journal of Cancer Therapy, 3(05), p.853.
Kollmannsberger C, Hirte H , Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Chen H, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A NCIC-CTG phase I, open-label, dose escalation study (IND 179) Annals of Oncology 2012;23(1);238-44
Elit, L.M., Lee, A.Y., Parpia, S., Swystun, L.L., Liaw, P.C., Hoskins, P., Julian, D.H., Julian, J.A. and Levine, M.N., 2012. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis research, 130(6), pp.894-900.
Grunfeld, E., Moineddin, R., Gunraj, N., Del Giudice, M.E., Hodgson, D.C., Kwon, J.S. and Elit, L., 2012. Cancer screening practices of cancer survivors Population-based, longitudinal study. Canadian Family Physician, 58(9), pp.980-986.
Schwartz, L., Hunt, M., Sinding, C., Elit, L., Redwood-Campbell, L., Adelson, N. and de Laat, S., 2012. Models for humanitarian health care ethics. Public Health Ethics, 5(1), pp.81-90.
Lawson, L., Lytwyn, A., Jang, D., Howard, M., Elit, L., Onuma, K., Klingel, M., Toor, R., Gilchrist, J., Ecobichon-Morris, A. and Smieja, M., 2012. Comparison of APTIMA HPV E6/E7 mRNA and Hybrid Capture 2 assays using wet and dry self-collected flocked vaginal swabs and PreservCyt L-Pap samples. Journal of Analytical Oncology, 1(2), pp.149-154.
Hunt, M.R., Schwartz, L., Sinding, C. and Elit, L., 2014. The ethics of engaged presence: a framework for health professionals in humanitarian assistance and development work. Developing world bioethics, 14(1), pp.47-55.
Hunt, M.R., Schwartz, L. and Elit, L., 2012. Experience of ethics training and support for health care professionals in international aid work. Public Health Ethics, 5(1), pp.91-99.
Akhtar-Danesh, N., Lytwyn, A. and Elit, L., 2012. Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecologic oncology, 127(3), pp.620-624.
Dodge, J.E., Covens, A.L., Lacchetti, C., Elit, L.M., Le, T., Devries–Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Management of a suspicious adnexal mass: a clinical practice guideline. Current oncology, 19(4), p.e244.
Trim, K., Nagji, N., Elit, L. and Roy, K., 2012. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstetrics and gynecology international, 2012.
Elit, L., Krzyzanowska, M., Saskin, R., Barbera, L., Razzaq, A., Lofters, A., Yeritsyan, N. and Bierman, A., 2012. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Canadian Family Physician, 58(1), pp.e22-e31.
Covens, A.L., Dodge, J.E., Lacchetti, C., Elit, L.M., Le, T., Devries-Aboud, M., Fung-Kee-Fung, M. and Gynecology Cancer Disease Site Group, 2012. Surgical management of a suspicious adnexal mass: a systematic review. Gynecologic oncology, 126(1), pp.149-156.
Akhtar-Danesh, N., Elit, L. and Lytwyn, A., 2012. Temporal trends in the relative survival among women with cervical cancer in Canada: a population-based study. International Journal of Gynecological Cancer, 22(7), pp.1208-1213.
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S. and Helland, H., 2012. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of oncology, 23(5), pp.1185-1189.
Waldo Jimenez
MD
Associate Professor
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Waldo Jimenez
MD
Associate Professor
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.